Along with COVID-19 and the flu, respiratory syncytial virus (RSV) has spread at alarming rates in recent months. Promising vaccine candidates for this common infection are now winding down their large-scale clinical trials. These vaccine candidates rely on a key advance made by Barney Graham, Jason McLellan, and colleagues in 2013. That year, Graham and McLellan, who later used similar approaches to make key contributions to the COVID-19 vaccines, provided the proof of concept for a new way of developing vaccines based on leveraging insights from structural biology . Together with colleague Man Chen, they made discoveries that paved the way for RSV vaccines that have neared the finish line , a feat Science Magazine named as a runner-up for the 2022 Breakthrough of the Year.
Come join Science Magazine on 1 March at 1 p.m. ET to hear Graham, McLellan, and Chen discuss how the approach they described in 2013 is leading to what could be the first ever FDA-approved vaccines against RSV, as well as other RSV therapeutics. Gregory Zuckerman, author of multiple best-selling books, including A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine , will share his perspective on this milestone.
Join us live at 1pm US ET on March 1 here: https://www.facebook.com/events/1127517927912679
We encourage you to post your questions at the Facebook event link in advance!
Science